Quick Takeaways
- AVIR - Atea Pharmaceuticals, Inc. has 14 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 14 Insiders of Atea Pharmaceuticals, Inc.
- Symbol
- AVIR on Nasdaq
- Location
- Boston, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
There are no Buy or Sell transactions made by insiders since 05 Apr 2025
Atea Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | $22,198,343 | Mixed | 31 Jan 2026 | ||
| Andrea Corcoran | Chief Financial Officer, Executive Vice President, Legal and Secretary | $3,449,970 | Mixed | 11 Mar 2026 | ||
| Franklin M. Berger | Director | $1,526,418 | Mixed | 20 Jun 2025 | ||
| John Vavricka | Chief Commercial Officer | $671,526 | Mixed | 31 Jan 2026 | ||
| Janet Mj Hammond | Chief Development Officer | $575,724 | Mixed | 31 Jan 2026 | ||
| Maria Arantxa Horga | Chief Medical Officer | $437,239 | Mixed | 31 Jan 2026 | ||
| Bruno Lucidi | Director | $419,989 | Mixed | 20 Jun 2025 | ||
| Bruce Polsky | Director | $385,928 | Mixed | 20 Jun 2025 | ||
| Wayne Foster | EVP, Chief Accounting Officer | $363,245 | Mixed | 31 Jan 2026 | ||
| Polly A. Murphy | Director | $360,186 | Mixed | 20 Jun 2025 | ||
| Barbara Gayle Duncan | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Jerome M. Adams | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Arthur S. Kirsch | Director | $139,873 | Mixed | 20 Feb 2025 | ||
| Howard Berman | Director | Mixed | 20 Jun 2025 |
Recent Insider Transactions by Companies or Individuals for Atea Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.86% | 60,000 | 823,576 | 11 Mar 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Options Exercise | 60,000 | 0 | 11 Mar 2026 | Direct | |||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 64.1% | 300,000 | 767,830 | 03 Feb 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Stock Option (Right to Buy) | Options Exercise | -100% | -300,000 | 0 | 03 Feb 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Tax liability | -14.3% | -16,073 | 96,086 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Options Exercise | 84.2% | 51,283 | 112,159 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Stock Option (Right to Buy) | Award | 173,500 | 173,500 | 31 Jan 2026 | Direct | |||
| Maria Arantxa Horga | AVIR | Restricted Stock Units | Options Exercise | -100% | -51,283 | 0 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Tax liability | -12.3% | -11,570 | 82,594 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Options Exercise | 80.8% | 42,083 | 94,164 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Stock Option (Right to Buy) | Award | 119,520 | 119,520 | 31 Jan 2026 | Direct | |||
| John Vavricka | AVIR | Restricted Stock Units | Options Exercise | -100% | -42,083 | 0 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Tax liability | -9.97% | -14,136 | 127,665 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Options Exercise | 69.3% | 58,050 | 141,801 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Stock Option (Right to Buy) | Award | 177,000 | 177,000 | 31 Jan 2026 | Direct | |||
| Janet Mj Hammond | AVIR | Restricted Stock Units | Options Exercise | -100% | -58,050 | 0 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Tax liability | -13.3% | -12,132 | 79,329 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Options Exercise | 82.4% | 41,333 | 91,461 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Stock Option (Right to Buy) | Award | 108,000 | 108,000 | 31 Jan 2026 | Direct | |||
| Wayne Foster | AVIR | Restricted Stock Units | Options Exercise | -100% | -41,333 | 0 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Tax liability | -2.07% | -16,104 | 763,576 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.57% | 54,866 | 779,680 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Award | 180,000 | 180,000 | 31 Jan 2026 | Direct | |||
| Andrea Corcoran | AVIR | Restricted Stock Units | Options Exercise | -100% | -54,866 | 0 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Tax liability | -18.5% | -106,093 | 467,830 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 90.7% | 272,983 | 573,923 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Restricted Stock Units | Options Exercise | -100% | -272,983 | 0 | 31 Jan 2026 | Direct | ||
| Polly A. Murphy | AVIR | Common Stock | Options Exercise | 52.4% | 29,600 | 86,045 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Polly A. Murphy | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Common Stock | Options Exercise | 6.21% | 29,600 | 506,497 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Common Stock | Options Exercise | 45.1% | 29,600 | 95,206 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruno Lucidi | AVIR | Common Stock | Options Exercise | 35.6% | 29,600 | 112,750 | 20 Jun 2025 | Direct | ||
| Bruno Lucidi | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Bruno Lucidi | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.